Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

• Status: Completed
• Trial end date: 2021-01-05

Summary

Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC

• Phase: Phase 2

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Cyclophosphamide; Docetaxel; Doxorubicin; Liposomal doxorubicin; Nivolumab; Paclitaxel; Pertuzumab; Trastuzumab